Hereditary Haemochromatosis — Research Summary
Printed from RareWays (rareways.com.au) on 26 July 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Estimates of European Ancestry in U.S. Hispanics Using
Barton James C et al. — Genetic testing and molecular biomarkers (30 June 2026)
https://pubmed.ncbi.nlm.nih.gov/42376730/
- 2.
Rapid Onset of Iron Overload Cardiomyopathy in Cirrhosis.
Nouraee Cyrus M et al. — JACC. Case reports (17 June 2026)
https://pubmed.ncbi.nlm.nih.gov/42126381/
- 3.
Expansion of CD101⁻ neutrophils drives susceptibility to hyperyersiniabactin-producing
Das Shreya et al. — Infection and immunity (12 June 2026)
https://pubmed.ncbi.nlm.nih.gov/42283579/
- 4.
In vivo base editing alleviates hepatic iron accumulation and fibrosis in models of HFE-related hereditary hemochromatosis.
Hamann Vanessa et al. — Journal of hepatology (10 June 2026)
https://pubmed.ncbi.nlm.nih.gov/42269836/
- 5.
Hereditary Hemochromatosis and Hypertrophic Cardiomyopathy as Tier 1 Genomic Conditions: Implications for Adult Population Genomic Screening.
Grosse Scott D et al. — Public health genomics (10 June 2026)
https://pubmed.ncbi.nlm.nih.gov/42268791/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
Recruiting — Phase 2 — CSL Behring
https://clinicaltrials.gov/study/NCT07332091
- 2.
A Study to Evaluate BBI-001 in Healthy Volunteers and in Patients With Hereditary Hemochromatosis
Recruiting — Phase 1 — Bond Biosciences
https://clinicaltrials.gov/study/NCT07371793
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Hereditary Haemochromatosis
Hereditary haemochromatosis is a genetic condition where the body absorbs too much iron from food, leading to iron build-up in the liver, heart, and other organs. It is the most common genetic condition in people of Northern European descent. Early detection and regular blood removal (phlebotomy) can prevent serious complications.
Most Recent Research
BACKGROUND: We estimated European ancestry in U.S. Hispanics using HFE p.C282Y (c.845G > A; rs1800562), a highly informative autosomal marker of European ancestry. METHODS: We tabulated published p.C282Y allele frequencies in U.S. Hispanic control/population region/city cohorts. We assumed that Hispanics inherited p.C282Y from European ancestors only. We defined European ancestry (M) of each cohort as the quotient of its published p.C282Y frequency by the published aggregate p.C282Y frequency in Iberian Spaniards. We compared the present average region/city values of M and the aggregate M with previous European ancestries of U.S. Hispanics estimated using multiple ancestry-informative markers (AIMs). RESULTS: There were 14,472 Hispanics (nine region/city cohorts; aggregate p.C282Y frequency 0.0176 [509/28,944] [95% confidence interval: 0.0159, 0.0189]). There were 12,297 Spaniards (34 population/control cohorts; aggregate p.C282Y frequency 0.0291 (716/24,594) [0.0271, 0.0313]). Nine region/city estimates of M differed 2.6-fold: Alabama 1.0000, California/Irvine 0.5395, California/Oakland 0.6186; California/San Diego 0.9381; Connecticut 0.6873; District of Columbia 0.3883; Hawaii 0.6976; New York 0.4330; and Oregon 1.0000. The average of these nine region/city estimates of M was 0.7003. The aggregate estimate of M in the present 14,472 Hispanics was 0.6048 [0.5369, 0.6728]. The range of estimated European ancestries in 29,365 Hispanics in eight previous studies that used multiple AIMs was 0.502-0.683. CONCLUSIONS: European ancestry in U.S. Hispanics estimated using p.C282Y frequencies varies across regions/cities. The average nine region/city and aggregate European ancestry estimates in the present U.S. Hispanics are similar to those in eight previous studies that used multiple AIMs.
Common Questions
What is Hereditary Haemochromatosis?
Hereditary haemochromatosis is a genetic condition where the body absorbs too much iron from food, leading to iron build-up in the liver, heart, and other organs. It is the most common genetic condition in people of Northern European descent. Early detection and regular blood removal (phlebotomy) can prevent serious complications.
How many clinical trials are available for Hereditary Haemochromatosis?
RareWays currently indexes 55 clinical trials for Hereditary Haemochromatosis, of which 3 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Hereditary Haemochromatosis come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Hereditary Haemochromatosis.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.